tetano
Editor, Senior Moderator
J Med Virol
. 2024 Nov;96(11):e70067.
doi: 10.1002/jmv.70067. A Herpes Simplex Virus Type-1-Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge
Paul J F Rider[SUP] 1 2 [/SUP], Harrison Dulin[SUP] 3 [/SUP], Ifeanyi K Uche[SUP] 1 2 [/SUP], Michael C McGee[SUP] 2 [/SUP], Weishan Huang[SUP] 2 4 [/SUP], Konstantin G Kousoulas[SUP] 1 2 [/SUP], Rong Hai[SUP] 3 [/SUP]
Affiliations
Influenza virus is a major respiratory viral pathogen responsible for the deaths of hundreds of thousands worldwide each year. Current vaccines provide protection primarily by inducing strain-specific antibody responses with the requirement of a match between vaccine strains and circulating strains. It has been suggested that anti-influenza T-cell responses, in addition to antibody responses may provide the broadest protection against different flu strains. Therefore, to address this urgent need, it is desirable to develop a vaccine candidate with an ability to induce balanced adaptive immunity including cell mediated immune responses. Here, we explored the potential of VC2, a well-characterized Herpes Simplex Virus type 1 vaccine vector, as a live attenuated influenza vaccine candidate. We generated a recombinant VC2 virus expressing the influenza A hemagglutinin protein. We show that this virus is capable of generating potent and specific anti-influenza humoral and cell-mediated immune responses. We further show that a single vaccination with the VC2-derived influenza vaccine protects mice from lethal challenge with influenza virus. Our data support the continued development of VC2-derived influenza vaccines for protection of human populations from both seasonal and pandemic strains of influenza. Finally, our results support the potential of VC2-derived vaccines as a platform for the rapid development of vaccines against emerging and established pathogens, particularly respiratory pathogens.
Keywords: cell‐mediated immunity; disease control; immune responses; influenza virus; vaccines/vaccine strains; virus classification.
. 2024 Nov;96(11):e70067.
doi: 10.1002/jmv.70067. A Herpes Simplex Virus Type-1-Derived Influenza Vaccine Induces Balanced Adaptive Immune Responses and Protects Mice From Lethal Influenza Virus Challenge
Paul J F Rider[SUP] 1 2 [/SUP], Harrison Dulin[SUP] 3 [/SUP], Ifeanyi K Uche[SUP] 1 2 [/SUP], Michael C McGee[SUP] 2 [/SUP], Weishan Huang[SUP] 2 4 [/SUP], Konstantin G Kousoulas[SUP] 1 2 [/SUP], Rong Hai[SUP] 3 [/SUP]
Affiliations
- PMID: 39568407
- DOI: 10.1002/jmv.70067
Influenza virus is a major respiratory viral pathogen responsible for the deaths of hundreds of thousands worldwide each year. Current vaccines provide protection primarily by inducing strain-specific antibody responses with the requirement of a match between vaccine strains and circulating strains. It has been suggested that anti-influenza T-cell responses, in addition to antibody responses may provide the broadest protection against different flu strains. Therefore, to address this urgent need, it is desirable to develop a vaccine candidate with an ability to induce balanced adaptive immunity including cell mediated immune responses. Here, we explored the potential of VC2, a well-characterized Herpes Simplex Virus type 1 vaccine vector, as a live attenuated influenza vaccine candidate. We generated a recombinant VC2 virus expressing the influenza A hemagglutinin protein. We show that this virus is capable of generating potent and specific anti-influenza humoral and cell-mediated immune responses. We further show that a single vaccination with the VC2-derived influenza vaccine protects mice from lethal challenge with influenza virus. Our data support the continued development of VC2-derived influenza vaccines for protection of human populations from both seasonal and pandemic strains of influenza. Finally, our results support the potential of VC2-derived vaccines as a platform for the rapid development of vaccines against emerging and established pathogens, particularly respiratory pathogens.
Keywords: cell‐mediated immunity; disease control; immune responses; influenza virus; vaccines/vaccine strains; virus classification.